The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy.
Rev Soc Bras Med Trop
; 47(4): 528-32, 2014 Jul.
Article
em En
| MEDLINE
| ID: mdl-25229299
Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfill criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced significantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Paraparesia Espástica Tropical
/
Toxinas Botulínicas Tipo A
/
Bexiga Urinária Hiperativa
/
Inibidores da Liberação da Acetilcolina
Tipo de estudo:
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Rev Soc Bras Med Trop
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Brasil